Cogent Biosciences

NASDAQ:COGT
Develops antibody-coupled T-cell receptor platform to target and kill tumor cells.
Develops antibody-coupled T-cell receptor platform to target and kill tumor cells.

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2014
Cogent Biosciences

Cogent Biosciences (NASDAQ:COGT) (formerly Unum Therapeutics) has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells.